University of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN)

University of Texas Texas AM Investment Management Co. purchased a new stake in Aileron Therapeutics, Inc. (NASDAQ:ALRN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,777,827 shares of the company’s stock, valued at approximately $4,925,000. Aileron Therapeutics comprises about 1.0% of University of Texas Texas AM Investment Management Co.’s investment portfolio, making the stock its 20th biggest position. University of Texas Texas AM Investment Management Co. owned about 8.22% of Aileron Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ALRN. Texas Capital Bank Wealth Management Services Inc grew its holdings in Aileron Therapeutics by 65.9% in the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock valued at $174,000 after buying an additional 10,398 shares in the last quarter. Warberg Asset Management LLC acquired a new position in shares of Aileron Therapeutics during the 2nd quarter valued at about $86,000. Finally, Nantahala Capital Management LLC grew its holdings in shares of Aileron Therapeutics by 82.1% in the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock valued at $1,286,000 after purchasing an additional 209,367 shares during the period. Institutional investors and hedge funds own 90.89% of the company’s stock.

Aileron Therapeutics Price Performance

NASDAQ:ALRN opened at $3.62 on Wednesday. The company’s 50-day moving average is $2.59 and its two-hundred day moving average is $3.57. Aileron Therapeutics, Inc. has a 1-year low of $1.01 and a 1-year high of $7.42. The firm has a market capitalization of $78.25 million, a price-to-earnings ratio of -1.13 and a beta of 2.33.

Aileron Therapeutics (NASDAQ:ALRN) last posted its earnings results on Wednesday, August 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.20). As a group, equities analysts anticipate that Aileron Therapeutics, Inc. will post -1.41 earnings per share for the current fiscal year.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).